Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.90 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL5328814 | 1.00 | CA4 (0.90) | CA4FAHD1CASP1FFAR3HDAC3 | |
| Citric Acid SCHEMBL22124526 | 0.97 | CA4 (0.85) | CA4FAHD1CASP1 | |
| Citric Acid SCHEMBL989893 | 0.97 | CA4 (0.94) | CA4FAHD1CASP1FFAR3HDAC3 | |
| Citric Acid SCHEMBL6690080 | 0.97 | CA4 (0.94) | CA4FAHD1CASP1FFAR3HDAC3 | |
| Citric Acid SCHEMBL6687136 | 0.97 | CA4 (0.94) | CA4FAHD1CASP1FFAR3HDAC3 | |
| Citric Acid SCHEMBL29374581 | 0.97 | CA4 (0.94) | CA4FAHD1CASP1FFAR3HDAC3 | |
| Citric Acid SCHEMBL8066143 | 0.97 | CA4 (0.94) | CA4FAHD1CASP1FFAR3HDAC3 | |
| Citric Acid SCHEMBL212319 | 0.97 | CA4 (0.94) | CA4FAHD1CASP1FFAR3HDAC3 | |
| Citric Acid SCHEMBL23672268 | 0.95 | CA4 (0.90) | CA4FAHD1CASP1FFAR3HDAC3 | |
| Citric Acid SCHEMBL21626215 | 0.95 | CA4 (0.90) | CA4CASP1FFAR3HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470675-B2 | Methods for treating cancer using interferon-ω-expressing polynucleotides | VICAL INCORPORATED (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070225243-A1 | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor | HORTON HOLLY | 2007-09-27 | — | — | US | disclosed |
| US-7268120-B1 | Methods for treating cancer using cytokine-expressing polynucleotides | VICAL INCORPORATED (US) | 2007-09-11 | — | — | US | disclosed |
| US-6875748-B2 | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics | VICAL INCORPORATED (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1278551-A2 | COMPOSITIONS AND METHODS FOR (IN VIVO) DELIVERY OF POLYNUCLEOTIDE-BASED THERAPEUTICS | VICAL INCORPORATED (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020019358-A1 | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics | VICAL INCORPORATED | 2002-02-14 | — | — | US | disclosed |
| WO-2001080897-A2 | COMPOSITIONS AND METHODS FOR IN VIVO DELIVERY OF POLYNUCLEOTIDE-BASED THERAPEUTICS | VICAL INCORPORATED (US) | 2001-11-01 | — | — | WO | disclosed |
| US-5038396-A | Mixture of isphagula husk, swelling agent, electrolyte, glucose, binder | VERSCHOOR, JACOB | 1991-08-06 | — | — | US | disclosed |